IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by TD Private Client Wealth LLC

TD Private Client Wealth LLC decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 951 shares of the medical research company’s stock after selling 80 shares during the quarter. TD Private Client Wealth LLC’s holdings in IQVIA were worth $187,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in IQV. Smith Group Asset Management LLC purchased a new position in IQVIA during the 4th quarter worth approximately $1,616,000. Nordea Investment Management AB grew its position in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Hickory Asset Management Inc. acquired a new position in shares of IQVIA in the 4th quarter valued at $941,000. Fifth Third Bancorp raised its position in IQVIA by 13.0% in the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock valued at $2,590,000 after purchasing an additional 1,521 shares during the last quarter. Finally, Graphene Investments SAS boosted its stake in IQVIA by 22.0% during the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock worth $2,948,000 after purchasing an additional 2,700 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of research reports. Stifel Nicolaus reduced their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. Morgan Stanley increased their price objective on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. BTIG Research lowered IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Stephens initiated coverage on IQVIA in a report on Friday, December 20th. They set an “overweight” rating and a $250.00 price target for the company. Finally, UBS Group dropped their price objective on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Five equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Stock Performance

NYSE IQV opened at $181.07 on Wednesday. IQVIA Holdings Inc. has a 1-year low of $179.28 and a 1-year high of $253.84. The company has a market capitalization of $31.93 billion, a P/E ratio of 24.14, a PEG ratio of 1.99 and a beta of 1.50. The business has a 50 day moving average price of $194.24 and a 200 day moving average price of $207.29. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.